---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-036694"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2022-07-01T23:59:59+00:00"
generated_at: "2026-06-24T21:51:06.831939+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nektar Therapeutics CFO/COO steps down; Jillian Thomsen named CFO; CCO separation detailed

## Summary
- Gil Labrucherie steps down as CFO and COO effective July 1, 2022.
- Jillian Thomsen promoted from SVP Finance and CAO to SVP and CFO effective July 1, 2022.
- John Northcott, SVP and CCO, separated June 30, 2022; receives $921,206 lump sum severance.
- Northcott gets consulting retainer of $20k/month for up to 60 hours, $335/hr thereafter through Dec 31, 2022.
- Vested options for Northcott remain exercisable until June 30, 2023; no further vesting of unvested awards.

## SEC filing metadata
- accession: 0001213900-22-036694
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2022-07-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390022036694/0001213900-22-036694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390022036694/ea162348-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-036694
- JSON: https://secwatch.observer/filing/0001213900-22-036694.json
- Plain text: https://secwatch.observer/filing/0001213900-22-036694.txt

## Key facts
- Executive change
  Gil Labrucherie departed as Chief Financial Officer and Chief Operating Officer at NEKTAR THERAPEUTICS.
  - Action: step down
  - Role: Chief Financial Officer and Chief Operating Officer
  source text: On July 1, 2022, Nektar Therapeutics (the “Company”) announced that Gil Labrucherie will step down as Chief Financial Officer and Chief Operating Officer of the Company, effective as of July 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390022036694/0001213900-22-036694-index.htm
- Executive change
  John Northcott departed as Senior Vice President and Chief Commercial Officer at NEKTAR THERAPEUTICS.
  - Action: step down
  - Role: Senior Vice President and Chief Commercial Officer
  source text: On April 25, 2022 (the “Notice Date”), the Company announced that John Northcott will step down from the role of Senior Vice President and Chief Commercial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390022036694/0001213900-22-036694-index.htm
- Executive change
  Jillian Thomsen changed role as Senior Vice President and Chief Financial Officer at NEKTAR THERAPEUTICS.
  - Action: promoted
  - Role: Senior Vice President and Chief Financial Officer
  source text: On July 1, 2022, the Company announced the promotion of Jillian Thomsen, who currently serves as Senior Vice President, Finance and Chief Accounting Officer, to the position of Senior Vice President and Chief Financial Officer, effective as of July 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390022036694/0001213900-22-036694-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.